Study of Personalized Tumour Vaccines and a PD-L1 Blocker in Patients With Surgically Resected Pancreatic Adenocarcino

Conditions: Pancreatic Cancer Interventions: Drug: Adebrelimab; Drug: mRNA tumor vaccines Sponsors: Fudan University; Shanghai Regenelead Therapies Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials